Novel Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) for Future Hepatology

Hiroshi Bando

doi:10.36502/2023/droa.6184

Novel Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) for Future Hepatology | Abstract

Diabetes Research: Open Access

Article Type: Editorial

DOI: 10.36502/2023/droa.6184

Diab Res Open Access. 2023 Oct 03;4(1):8-11

Full Text HTML

Full Text PDF

Hiroshi Bando^1,2iD*
¹Medical Research/Tokushima University, Tokushima, Japan
²Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Kyoto, Japan

Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ^{ORCID iD}
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 19 August 2023; Accepted date: 15 September 2023; Published date: 03 October 2023

Citation: Bando H. Novel Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) for Future Hepatology. Diab Res Open Access. 2023 Oct 03;4(1):08-11.

Copyright © 2023 Bando H. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, American Association for the Study of Liver Diseases

Abbreviations: MASLD: Metabolic Dysfunction-Associated Steatotic Liver Disease; MASH: Metabolic Dysfunction-Associated Steatohepatitis; MetALD: Metabolic Dysfunction-Associated Steatotic Liver Disease; NAFLD: Non-Alcoholic Fatty Liver Disease; AASLD: American Association for the Study of Liver Diseases

Abstract

Type 2 diabetes (T2D) has close relationships with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and others. The European Hepatology Society International Hepatology Conference (EASL-ILC) 2023 presented the announcement of novel nomenclatures for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Furthermore, metabolic dysfunction-associated steatotic liver disease (MetALD) is used to describe those who consume greater amounts of alcohol, defined as more than 210g per week for males and more than 140g per week for females. MASLD may affect about one quarter of adults worldwide. Its criteria include the evidence of hepatic steatosis in three situations: obesity/overweight, T2DM, or the presence of metabolic dysfunction.